The promise and peril of GLP-1 agonists: What we do (and don't) know as of August 2024 Yulan Egan Aug 21, 2024 6 min read Across the past two years, GLP-1 agonistsa class of drugs that treat type 2 diabetes (T2D) and obesityhave not only become a major source of industry discourse, but a household name
Between 2016 and 2019, a total of 35 patients were enrolled in the trial and randomly assigned to groups (Figure 1)
As a result, the regulatory framework governing compounded GLP-1 medications continues to change
GLP-1 medicines such as semaglutide and tirzepatide work with your body's own signaling to influence appetite and how full you feel
Dual amylin and calcitonin receptor agonist treatment improves insulin sensitivity and increases muscle-specific glucose uptake independent of weight loss
To consider them anti-aging drugs that can extend life expectancy doesnt just create unrealistic expectations but also increases the risk that theyll be misused by people who dont need them or arent using them under medical supervision, Dr
